EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extracorporeal Albumin Dialysis ( OPAL ) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure

Dorian Marckmann iD, Emely Wack, Luisa Schäfer, H Christian Hillebrecht iD, Francesca Reimer, Gabriel Stöger, Klara Krötzsch, Magdalena Menzel, Lampros Kousoulas, Stefan Utzolino, Stefan Fichtner-Feigl, Dawid L Staudacher und 5 weitere

Artificial Organs · 2026

DOI: 10.1111/aor.70187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2026. Verfasst von Dorian Marckmann und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Visceral Surgery, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Liver Failure, Hepatectomy, Renal Dialysis, Postoperative Complications. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg, Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie, Universität Zürich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Posthepatectomy liver failure (PHLF) remains a major cause of mortality after liver resection, with limited therapeutic options. PHLF can be categorized into primary (small‐for‐size) and secondary forms, the latter resulting from complications such as sepsis or hemorrhage. Extracorporeal albumin dialysis (ECAD), including open albumin dialysis (OPAL), may support hepatic detoxification by removing albumin‐bound toxins. While most studies focus on primary PHLF, data on secondary PHLF are scarce.

Methods

This retrospective cohort study includes all patients receiving OPAL after liver surgery until February 2026 at the Medical Center of the University of Freiburg, Germany. A detailed chart review was performed. The primary endpoint was bilirubin reduction per filter cycle. Survival and changes in laboratory parameters were analyzed as secondary endpoints.

Results

Eighteen patients were included, predominantly with secondary PHLF (15/18, 83.3%). Sepsis was the leading cause of secondary liver failure (8/15, 53.3%), followed by hemorrhage (6/15, 40.0%). Median bilirubin reduction per filter cycle was 1.52 mg/dL (relative reduction 14.64%; p < 0.0001), with greater reductions at higher prefilter levels ( p < 0.0001). Relative reductions were also observed in creatinine (16.84%) and urea (14.75%; both p < 0.0001). Platelet count and hemoglobin showed minor decreases, while MELD 3.0 scores improved modestly. Multiple consecutive filters did not increase overall bilirubin reduction. Thirty‐day survival after surgery was 66.7% and 38.9% after OPAL initiation.

Conclusion

OPAL effectively reduces bilirubin levels and improves related parameters in PHLF. It may provide temporary detoxification support, particularly in secondary PHLF. Prospective studies are needed to assess its impact on patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver FailureHepatectomyRenal DialysisPostoperative ComplicationsAlbuminsHumansRetrospective StudiesFemaleMiddle AgedMaleAgedBilirubinBridge TherapyTreatment OutcomeSepsis

Substanzen

BilirubinAlbumins

Autor:innen und Institutionen

  • Department of General and Visceral Surgery, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Interdisciplinary Medical Intensive Care, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Medicine IV - Nephrology and Primary Care, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.
  • Zurich Kidney Center, Zurich, Switzerland.
  • German Cancer Consortium (DKTK) Partner Site, Freiburg, Germany.

ORCID-Profile: Dorian Marckmann, H Christian Hillebrecht, Frederic Arnold, Felix A Rottmann

Förderung

  • Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg
  • Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie
  • Universität Zürich

Zitieren

APA

Marckmann, D., Wack, E., Schäfer, L., Hillebrecht, H. C., Reimer, F., Stöger, G., Krötzsch, K., Menzel, M., Kousoulas, L., Utzolino, S., Fichtner-Feigl, S., Staudacher, D. L., Arnold, F., Welte, T., Holzner, P., Rottmann, F. A., & Berlin, C. (2026). Extracorporeal Albumin Dialysis ( OPAL ) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure. Artificial Organs. https://doi.org/10.1111/aor.70187

Vancouver

Marckmann D, Wack E, Schäfer L, Hillebrecht HC, Reimer F, Stöger G, et al. Extracorporeal Albumin Dialysis ( OPAL ) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure. Artificial Organs. 2026. doi:10.1111/aor.70187

BibTeX
@article{Marckmann2026,
  author = {Marckmann, Dorian and Wack, Emely and Schäfer, Luisa and Hillebrecht, H Christian and Reimer, Francesca and Stöger, Gabriel and Krötzsch, Klara and Menzel, Magdalena and Kousoulas, Lampros and Utzolino, Stefan and Fichtner-Feigl, Stefan and Staudacher, Dawid L and Arnold, Frederic and Welte, Thomas and Holzner, Philipp and Rottmann, Felix A and Berlin, Christopher},
  title = {Extracorporeal Albumin Dialysis ( OPAL ) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure},
  journal = {Artificial Organs},
  year = {2026},
  doi = {10.1111/aor.70187}
}
Kostenlos starten →